Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 1, 2020updated 22 Nov 2021 8:21am

Inovio Covid-19 vaccine shows promise in early-stage trial

Inovio Pharmaceuticals has reported positive interim results from the initial two cohorts in Phase I clinical trial of its Covid-19 vaccine candidate, INO-4800.

Inovio Pharmaceuticals has reported positive interim results from the initial two cohorts in Phase I clinical trial of its Covid-19 vaccine candidate, INO-4800.

With funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Phase I trial initially recruited 40 healthy adults aged 18 to 50 years at two sites in the US. Participants were given two 1mg or 2mg doses of INO-4800 four weeks apart.

An analysis by independent Data Safety Monitoring Board showed that the Inovio Covid-19 vaccine candidate was generally safe and well-tolerated in all participants across both cohorts through week 8.

The company added that all ten reported adverse events (AEs) were grade 1 in severity, without any serious adverse events (SAEs).

Immunology assays, including tests for humoral and cellular immune responses, are being performed for both INO-4800 dose cohorts following two doses at week 6.

So far, preliminary data on humoral and T cell immune responses has revealed that 94% of total participants experienced overall immunological response rates.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Apart from the positive interim Phase I results, the company announced that INO-4800 was able to protect mice in SARS-CoV-2 viral challenge studies, where the vaccine candidate prevented viral replication in the lungs of animals.

Furthermore, INO-4800 has been chosen to be part of a non-human primate (NHP) challenge study under the US Government’s Operation Warp Speed programme.

Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “We are very encouraged by the positive interim safety and preliminary cellular and humoral immune response results to date as well as the inclusion of INO-4800 in Operation Warp Speed.

“We are also pleased that INO-4800 vaccination abrogated viral replication in the lungs of mice challenged with SARS-CoV-2.”

The company has expanded the Phase I trial to include older participants in additional cohorts. It also intends to launch a Phase II/III efficacy trial in the coming months.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU